NCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
Clinical Trials
22 trialsNCT06912763 2026-01-26
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04238637 2025-12-05
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT07150247 2025-09-26
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT07174947 2025-09-16
SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06207734 2025-05-01
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT01973322 2025-01-09
ABSIDE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT04760327 2024-10-17
GynECT
Institute of Oncology Ljubljana
Phase 2 Recruiting
NCT03753659 2024-07-22
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT00596154 2024-04-01
PCNSL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00318903 2023-05-25
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT03841201 2023-05-12
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03698227 2020-07-15
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Terminated
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT00526656 2019-04-16
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03048123 2017-02-09
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
Sun Yat-sen University
Phase 2 Completed
NCT00210392 2015-03-30
VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Terminated
NCT00203879 2013-09-05
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
University of Chicago
Phase 2 Completed
NCT00210327 2009-07-22
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT00167908 2009-02-04
Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00695370 2008-06-13
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
University Hospital, Clermont-Ferrand
Phase 2 Terminated
NCT00319007 2007-08-10
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
Radboud University Medical Center
Phase 2 Unknown